GnRH-Rezeptor-vermittelte Tumortherapie

Einleitung

Eine Rezeptor-vermittelte Therapie zeichnet sich dadurch aus, dass nur Zellen therapiert werden, die den entsprechenden Rezeptor an ihrer Zelloberfläche tragen. Zellen, welche die Rezeptoren nicht besitzen, werden geschont. Der Vorteil der Rezeptor-vermittelten Therapie über G-Protein-gekoppelte Membranrezeptoren gegenüber anderen zielzellspezifischen Verfahren, wie der Therapie mit Antikörpern, ist, dass der Ligand nach Bindung an den Rezeptor in die Zelle aufgenommen wird. Antikörper bleiben dagegen in der Regel an der Zelloberfläche lokalisiert, was deren Wirkspektrum stark einschränkt.

Literatur

• 1 Grundker C, Gunthert A R, Westphalen S, Emons G. Biology of the gonadotropin-releasing hormone system in gynecological cancers.  Eur J Endocrinol. 2002;  146 1-14
• 2 Gründker C, Emons G. GnRH in cancers of reproductive organs. Lunenfeld B GnRH Analogs in Human Reproduction. London; Taylor and Francis 2005: 16-28
• 3 Grundker C. Cytotoxic luteinizing hormone-releasing hormone conjugates and their use in gynecological cancer therapy.  Eur J Endocrinol. 2000;  143 569-572
• 4 Günthert A R, Gründker C, Bongertz T, Nagy A, Schally A V, Emons G. Induction of apoptosis by AN‐152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH‐R positive human breast cancer cells is independent of multidrug resistance-1 (MDR‐1) system.  Breast Cancer Res Treat. 2004;  87 255-264
• 5 Westphalen S, Kotulla G, Kaiser F, Krauss W, Werning G, Elsasser H P. et al . Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN‐152 in human ovarian and endometrial cancer cell lines.  Int J Oncol. 2000;  17 1063-1069
• 6 Krebs L J, Wang X, Pudavar H E, Bergey E J, Schally A V, Nagy A. et al . Regulation of targeted chemotherapy with cytotoxic lutenizing hormone-releasing hormone analogue by epidermal growth factor.  Cancer Res. 2000;  60 4194-4199
• 7 Grundker C, Volker P, Griesinger F, Ramaswamy A, Nagy A, Schally A V. et al . Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN‐152 on human endometrial and ovarian cancers xenografted into nude mice.  Am J Obstet Gynecol. 2002;  187 528-537
• 8 Gunthert A R, Grundker C, Bongertz T, Nagy A, Schally A V, Emons G. Induction of apoptosis by AN‐152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH‐R positive human breast cancer cells is independent of multidrug resistance-1 (MDR‐1) system.  Breast Cancer Res Treat. 2004;  87 255-264
• 9 Gunthert A R, Grundker C, Bongertz T, Schlott T, Nagy A, Schally A V. et al . Internalization of cytotoxic analog AN‐152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR‐1) system.  Am J Obstet Gynecol. 2004;  191 1164-1172
• 10 Gründker C, Schulz K, Günthert A R, Emons G. Luteinizing hormone-releasing hormone induces nuclear factor kappaB-activation and inhibits apoptosis in ovarian cancer cells.  J Clin Endocrinol Metab. 2000;  85 3815-3820
• 11 Gründker C, Huschmand Nia A, Emons G. Gonadotropin-releasing hormone receptor-targeted gene therapy of gynecologic cancers.  Mol Cancer Ther. 2005;  4 225-231
• 12 Millar R P. GnRHs and GnRH receptors.  Anim Reprod Sci. 2005;  88 5-28
• 13 White R B, Eisen J A, Kasten T L, Fernald R D. Second gene for gonadotropin-releasing hormone in humans.  Proc Natl Acad Sci USA. 1998;  95 305-309
• 14 Urbanski H F, White R B, Fernald R D, Kohama S G, Garyfallou V T, Densmore V S. Regional expression of mRNA encoding a second form of gonadotropin-releasing hormone in the macaque brain.  Endocrinology. 1999;  140 1945-1948
• 15 Tensen C, Okuzawa K, Blomenrohr M, Rebers F, Leurs R, Bogerd J. et al . Distinct efficacies for two endogenous ligands on a single cognate gonadoliberin receptor.  Eur J Biochem. 1997;  243 134-140
• 16 Blomenrohr M, Heding A, Sellar R, Leurs R, Bogerd J, Eidne K A. et al . Pivotal role for the cytoplasmic carboxyl-terminal tail of a nonmammalian gonadotropin-releasing hormone receptor in cell surface expression, ligand binding, and receptor phosphorylation and internalization.  Mol Pharmacol. 1999;  56 1229-1237
• 17 Neill J D, Duck L W, Sellers J C, Musgrove L C. A gonadotropin-releasing hormone (GnRH) receptor specific for GnRH II in primates.  Biochem Biophys Res Commun. 2001;  282 1012-1018
• 18 Millar R, Lowe S, Conklin D, Pawson A, Maudsley S, Troskie B. et al . A novel mammalian receptor for the evolutionarily conserved type II GnRH.  Proc Natl Acad Sci USA. 2001;  98 9636-9641
• 19 Millar R, Conklin D, Lofton-Day C, Hutchinson E, Troskie B, Illing N. et al . A novel human GnRH receptor homolog gene: abundant and wide tissue distribution of the antisense transcript.  J Endocrinol. 1999;  162 117-126
• 20 Millar R P. GnRH II and type II GnRH receptors.  Trends Endocrinol Metab. 2003;  14 35-43
• 21 Grundker C, Gunthert A R, Millar R P, Emons G. Expression of gonadotropin-releasing hormone II (GnRH‐II) receptor in human endometrial and ovarian cancer cells and effects of GnRH‐II on tumor cell proliferation.  J Clin Endocrinol Metab. 2002;  87 1427-1430
• 22 Eicke N, Gunthert A R, Viereck V, Siebold D, Behe M, Becker T. et al . GnRH‐II receptor-like antigenicity in human placenta and in cancers of the human reproductive organs.  Eur J Endocrinol. 2005;  153 605-612
• 23 Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R. et al . High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines.  Cancer Res. 1993;  53 5439-5446
• 24 Emons G, Schroder B, Ortmann O, Westphalen S, Schulz K D, Schally A V. High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines.  J Clin Endocrinol Metab. 1993;  77 1458-1464
• 25 Grundker C, Schlotawa L, Viereck V, Eicke N, Horst A, Kairies B. et al . Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH‐II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor.  Eur J Endocrinol. 2004;  151 141-149
• 26 Eicke N, Gunthert A R, Emons G, Grundker C. GnRH‐II agonist [D-Lys6]GnRH‐II inhibits the EGF-induced mitogenic signal transduction in human endometrial and ovarian cancer cells.  Int J Oncol. 2006;  29) 1223-1229
• 27 Fister S, Gunthert A R, Emons G, Grundker C. Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo.  Cancer Res. 2007;  67 1750-1756